Aldevron Breakthrough Blog

Presentation: Building a Comprehensive mRNA Production Ecosystem

June 28, 2023 / by Aldevron

Aiming to eliminate unnecessary complexity

The manufacture and release of mRNA therapeutics and vaccines is a complex and challenging process that requires a high degree of expertise, capabilities, and experience. The production process involves several stages, including the production of cell banks, linear DNA, mRNA drug substance, LNP encapsulation, fill/finish, and analytical testing at each step. Each production stage must be executed with extreme care to ensure the final product's safety and efficacy.

Furthermore, when working with multiple contract development and manufacturing organizations (CDMOs), the management of logistics, tech transfer, release testing, shipping, storage, and analytical testing becomes complex and requires intense project management.

Aldevron has overcome this challenge by offering a comprehensive mRNA production ecosystem with sequence-to-vial capabilities under one-roof and quality system, thereby eliminating the unnecessary complexities of multiple CDMO exchanges while accelerating the program timeline.

As part of the rollout of our new mRNA services, Todd Howren, Vice President of RNA Client Services, provided an exclusive overview of the system at the TIDES USA conference in Boston. The presentation is now available for viewing and for you to share with your colleagues.




Aldevron serves the biotechnology industry with custom production of nucleic acids and proteins. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from research grade to clinical trials to commercial applications. Aldevron specializes in cGMP manufacturing and is known for inventing the GMP-SourceĀ® quality system. Aldevron operates the largest cGMP plasmid DNA manufacturing facility in the world at company headquarters in Fargo, North Dakota, with additional facilities in Madison, Wisconsin, and Lincoln, Nebraska.